

# Gábor Halmos

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11291953/publications.pdf>

Version: 2024-02-01

94  
papers

3,570  
citations

94381

37  
h-index

161767

54  
g-index

96  
all docs

96  
docs citations

96  
times ranked

1724  
citing authors

#	ARTICLE	IF	CITATIONS
1	Synthesis of potent antagonists of receptors for growth hormone-releasing hormone with antitumor and anti-inflammatory activity. <i>Peptides</i> , 2022, 150, 170716.	1.2	7
2	Expression of Growth Hormone-Releasing Hormone and Its Receptor Splice Variants in Primary Human Endometrial Carcinomas: Novel Therapeutic Approaches. <i>Molecules</i> , 2022, 27, 2671.	1.7	4
3	Development and Biochemical Characterization of Self-Immolative Linker Containing GnRH-III-Drug Conjugates. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5071.	1.8	6
4	Expression of Luteinizing Hormone-Releasing Hormone (LHRH) and Type-I LHRH Receptor in Transitional Cell Carcinoma Type of Human Bladder Cancer. <i>Molecules</i> , 2021, 26, 1253.	1.7	2
5	Hypothalamic Releasing Hormones. , 2020, , 43-68.		1
6	Correlation between the Expression of Angiogenic Factors and Stem Cell Markers in Human Uveal Melanoma. <i>Life</i> , 2020, 10, 310.	1.1	3
7	Expression of Somatostatin Receptor Subtypes (SSTR-1â€“SSTR-5) in Pediatric Hematological and Oncological Disorders. <i>Molecules</i> , 2020, 25, 5775.	1.7	4
8	Drugging the R-loop interactome: RNA-DNA hybrid binding proteins as targets for cancer therapy. <i>DNA Repair</i> , 2019, 84, 102642.	1.3	28
9	Suitability of GnRH Receptors for Targeted Photodynamic Therapy in Head and Neck Cancers. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5027.	1.8	8
10	Novel Crizotinibâ€“GnRH conjugates revealed the significance of lysosomal trapping in GnRH-based drug delivery systems. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5590.	1.8	5
11	Enhanced In Vitro Antitumor Activity of GnRH-III-Daunorubicin Bioconjugates Influenced by Sequence Modification. <i>Pharmaceutics</i> , 2018, 10, 223.	2.0	21
12	Synthesis and in vitro biochemical evaluation of oxime bond-linked daunorubicinâ€“GnRH-III conjugates developed for targeted drug delivery. <i>Beilstein Journal of Organic Chemistry</i> , 2018, 14, 756-771.	1.3	19
13	Characterization of luteinizing hormone-releasing hormone receptor type I (LH-RH-I) as a potential molecular target in OCM-1 and OCM-3 human uveal melanoma cell lines. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 933-941.	1.0	5
14	Experimental therapy of doxorubicin resistant human uveal melanoma with targeted cytotoxic luteinizing hormone-releasing hormone analog (AN-152). <i>European Journal of Pharmaceutical Sciences</i> , 2018, 123, 371-376.	1.9	4
15	Somatostatin Receptors as Molecular Targets in Human Uveal Melanoma. <i>Molecules</i> , 2018, 23, 1535.	1.7	4
16	Concurrence of chromosome 3 and 4 aberrations in human uveal melanoma. <i>Oncology Reports</i> , 2017, 37, 1927-1934.	1.2	6
17	Expression of miRNA-21 and miRNA-221 in clear cell renal cell carcinoma (ccRCC) and their possible role in the development of ccRCC. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 533.e21-533.e27.	0.8	45
18	Prognosis in human glioblastoma based on expression of ligand growth hormone-releasing hormone, pituitary-type growth hormone-releasing hormone receptor, its splicing variant receptors, EGF receptor and PTEN genes. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1641-1649.	1.2	8

#	ARTICLE	IF	CITATIONS
19	Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonist. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 2617-2622.	3.3	27
20	Novel antagonists of growth hormone-releasing hormone inhibit growth and vascularization of human experimental ovarian cancers. Cancer, 2012, 118, 670-680.	2.0	31
21	Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 3755-3760.	3.3	69
22	GHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cells. Cell Cycle, 2009, 8, 3149-3156.	1.3	37
23	Dose-dependent growth inhibition in vivo of PCa prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZa. Prostate, 2008, 68, 1763-1772.	1.2	31
24	Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin. Anti-Cancer Drugs, 2008, 19, 349-358.	0.7	19
25	Potential of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 1943-1946.	3.3	39
26	Growth inhibition of non-small-cell lung carcinoma by BN/GRP antagonist is linked with suppression of K-Ras, COX-2, and pAkt. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 18671-18676.	3.3	32
27	The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA and LuCa prostate cancers. Prostate, 2007, 67, 1339-1353.	1.2	19
28	Characterization of receptors for growth hormone-releasing hormone in human osteosarcomas and Ewing's sarcomas. International Journal of Oncology, 2006, 29, 463.	1.4	1
29	Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207. Prostate, 2006, 66, 200-210.	1.2	15
30	Targeted chemotherapy with cytotoxic bombesin analogue AN-215 inhibits growth of experimental human prostate cancers. International Journal of Cancer, 2006, 118, 222-229.	2.3	26
31	Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 14513-14518.	3.3	33
32	Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 10403-10407.	3.3	40
33	Lipopeptide antagonists of growth hormone-releasing hormone with improved antitumor activities. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 4610-4615.	3.3	22
34	Inhibition of growth of experimental human and hamster pancreatic cancers in vivo by a targeted cytotoxic bombesin analog. Suizo, 2006, 21, 384-386.	0.1	0
35	Characterization of receptors for growth hormone-releasing hormone in human osteosarcomas and Ewing's sarcomas. International Journal of Oncology, 2006, 29, 463-9.	1.4	0
36	Antagonists of bombesin/gastrin-releasing peptide decrease the expression of angiogenic and anti-apoptotic factors in human glioblastoma. Anti-Cancer Drugs, 2005, 16, 159-165.	0.7	13

#	ARTICLE	IF	CITATIONS
37	Inhibition of Growth of Experimental Human and Hamster Pancreatic Cancers In Vivo by a Targeted Cytotoxic Bombesin Analog. <i>Pancreas</i> , 2005, 31, 275-282.	0.5	22
38	Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-1. <i>Cancer</i> , 2005, 104, 1312-1321.	2.0	39
39	Targeted chemotherapy with cytotoxic bombesin analogue AN-215 can overcome chemoresistance in experimental renal cell carcinomas. <i>Cancer</i> , 2005, 104, 2266-2274.	2.0	17
40	Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers. <i>Prostate</i> , 2005, 64, 303-315.	1.2	42
41	Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins. <i>Endocrine-Related Cancer</i> , 2005, 12, 999-1009.	1.6	36
42	Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormone. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 10628-10633.	3.3	21
43	The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 17424-17429.	3.3	110
44	Receptors for luteinizing hormone releasing hormone (LHRH) expressed in human non-Hodgkin's lymphomas can be targeted for therapy with the cytotoxic LHRH analogue AN-207. <i>European Journal of Cancer</i> , 2005, 41, 2196-2202.	1.3	31
45	Antagonists of growth hormone releasing hormone and bombesin inhibit the expression of EGF/HER receptor family in H-69 small cell lung carcinoma. <i>Cancer Letters</i> , 2005, 226, 123-131.	3.2	16
46	Development of a polyclonal antiserum for the detection of the isoforms of the receptors for human growth hormone-releasing hormone on tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 15160-15165.	3.3	24
47	Increased activity of antagonists of growth hormone-releasing hormone substituted at positions 8, 9, and 10. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 1708-1713.	3.3	41
48	Effective Treatment of Experimental Androgen Sensitive and Androgen Independent Intraosseous Prostate Cancer With Targeted Cytotoxic Somatostatin Analogue AN-238. <i>Journal of Urology</i> , 2004, 171, 911-915.	0.2	21
49	Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas. <i>Cancer</i> , 2003, 98, 1401-1410.	2.0	42
50	Ligand-dependent and -independent effects of splice variant 1 of growth hormone-releasing hormone receptor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 9512-9517.	3.3	61
51	Expression of a splice variant of the receptor for GHRH in 3T3 fibroblasts activates cell proliferation responses to GHRH analogs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 196-200.	3.3	73
52	Expression of Growth Hormone-Releasing Hormone and Its Receptor Splice Variants in Human Prostate Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 4707-4714.	1.8	71
53	Changes in subcellular distribution of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) after treatment with the LH-RH antagonist cetorelix. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 961-965.	3.3	30
54	Inhibition of PC-3 human prostate cancers by analogs of growth hormone-releasing hormone (GH-RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity. <i>International Journal of Cancer</i> , 2002, 98, 624-629.	2.3	28

#	ARTICLE	IF	CITATIONS
55	Inhibition of growth and metastases of MDA-MB-435 human estrogen-independent breast cancers by an antagonist of growth hormone-releasing hormone. <i>Anti-Cancer Drugs</i> , 2001, 12, 761-768.	0.7	54
56	Inhibition of the UCI-107 human ovarian carcinoma cell line by a targeted cytotoxic analog of somatostatin, AN-238. <i>Cancer</i> , 2001, 92, 1168-1176.	2.0	23
57	Hypothalamic Hormones and Cancer. <i>Frontiers in Neuroendocrinology</i> , 2001, 22, 248-291.	2.5	235
58	Antagonists of Growth Hormone-Releasing Hormone and Somatostatin Analog RC-160 Inhibit the Growth of the OV-1063 Human Epithelial Ovarian Cancer Cell Line Xenografted into Nude Mice <sup>1</sup> . <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 2144-2152.	1.8	51
59	Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II. , 2000, 88, 1384-1392.		28
60	Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers. , 2000, 42, 295-303.		150
61	Potential of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways. <i>Prostate</i> , 2000, 44, 172-180.	1.2	60
62	Peptide analogs in the therapy of prostate cancer. <i>Prostate</i> , 2000, 45, 158-166.	1.2	109
63	Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice. <i>Breast Cancer Research and Treatment</i> , 2000, 59, 255-262.	1.1	33
64	Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice. <i>Breast Cancer Research and Treatment</i> , 2000, 60, 71-79.	1.1	69
65	in vivo inhibition of PC-3 human androgen-independent prostate cancer by a targeted cytotoxic bombesin analogue, AN-215. <i>International Journal of Cancer</i> , 2000, 88, 652-657.	2.3	60
66	Antagonists of Growth Hormone-Releasing Hormone and Vasoactive Intestinal Peptide Inhibit Tumor Proliferation by Different Mechanisms: Evidence from <i>in Vitro</i> Studies on Human Prostatic and Pancreatic Cancers <sup>1</sup> . <i>Endocrinology</i> , 2000, 141, 2120-2128.	1.4	54
67	RAPID COMMUNICATION: Human Ovarian Cancers Express Somatostatin Receptors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 3509-3512.	1.8	43
68	High Expression of Somatostatin Receptors and Messenger Ribonucleic Acid for Its Receptor Subtypes in Organ-Confined and Locally Advanced Human Prostate Cancers <sup>1</sup> . <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 2564-2571.	1.8	65
69	The presence of receptors for bombesin/GRP and mRNA for three receptor subtypes in human ovarian epithelial cancers. <i>Regulatory Peptides</i> , 2000, 90, 77-84.	1.9	76
70	HIGH INCIDENCE OF RECEPTORS FOR LUTEINIZING HORMONE-RELEASING HORMONE (LHRH) AND LHRH RECEPTOR GENE EXPRESSION IN HUMAN PROSTATE CANCERS. <i>Journal of Urology</i> , 2000, 163, 623-629.	0.2	161
71	in vivo inhibition of PC $\beta$ human androgen $\beta$ -independent prostate cancer by a targeted cytotoxic bombesin analogue, AN $\beta$ 215. <i>International Journal of Cancer</i> , 2000, 88, 652-657.	2.3	1
72	Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs. <i>Journal of Cancer Research and Clinical Oncology</i> , 1999, 125, 444-452.	1.2	39

#	ARTICLE	IF	CITATIONS
73	Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice. <i>American Journal of Obstetrics and Gynecology</i> , 1999, 180, 1095-1103.	0.7	41
74	Complete regression of MX-1 human breast carcinoma xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone-releasing hormone, AN-207. , 1999, 85, 2608-2615.		26
75	Inhibition of growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238. , 1999, 82, 592-598.		39
76	Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high affinity to human breast cancers. <i>Cancer Letters</i> , 1999, 136, 129-136.	3.2	46
77	Inhibition of the growth of caki-I human renal adenocarcinoma in Vivo by luteinizing hormone-releasing hormone antagonist cetorelix, somatostatin analog RC-160, and bombesin antagonist RC-3940-II. <i>Cancer</i> , 1998, 82, 909-917.	2.0	32
78	Bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II inhibit tumor growth and decrease the levels and mRNA expression of epidermal growth factor receptors in H-69 small cell lung carcinoma. <i>Cancer</i> , 1998, 83, 1335-1343.	2.0	54
79	New analogs of human growth hormone-releasing hormone (1-29) with high and prolonged antagonistic activity. <i>Chemical Biology and Drug Design</i> , 1998, 51, 134-141.	1.2	8
80	Targeted cytotoxic luteinizing hormone releasing hormone (LH-RH) analogs inhibit growth of estrogen independent MXT mouse mammary cancers in vivo by decreasing cell proliferation and inducing apoptosis. <i>Anti-Cancer Drugs</i> , 1997, 8, 974-987.	0.7	23
81	Luteinizing hormone-releasing hormone antagonist Cetorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice. , 1997, 32, 164-172.		54
82	Effect of a cytotoxic analog of LH-RH (T-98) on the growth of estrogendependent MXT mouse mammary cancers: Correlations between growth characteristics and EGF receptor content of tumors. <i>Breast Cancer Research and Treatment</i> , 1996, 40, 129-139.	1.1	11
83	Somatostatin analog RC-160 inhibits the growth of human osteosarcomas in nude mice. , 1996, 65, 870-874.		23
84	Inhibition of growth of MKN45 human gastric-carcinoma xenografts in nude mice by treatment with bombesin/gastrin-releasing-peptide antagonist (RC-3095) and somatostatin analogue RC-160. <i>International Journal of Cancer</i> , 1994, 57, 574-580.	2.3	78
85	Inhibitory effects of analogs of luteinizing hormone-releasing hormone on the growth of the androgen-independent dunning R-3327-AT-1 rat prostate cancer. <i>International Journal of Cancer</i> , 1994, 59, 51-55.	2.3	38
86	Bombesin antagonists inhibit in vitro and in vivo growth of human gastric cancer and binding of bombesin to its receptors. <i>Journal of Cancer Research and Clinical Oncology</i> , 1994, 120, 519-528.	1.2	47
87	Characterization of bombesin/gastrin-releasing peptide receptors in membranes of MKN45 human gastric cancer. <i>Cancer Letters</i> , 1994, 85, 111-118.	3.2	32
88	Inhibitory Effects of Antagonists of Bombesin/Gastrin Releasing Peptide (GRP) and Somatostatin Analog (RC-160) on Growth of HT-29 Human Colon Cancers in Nude Mice. <i>Acta Oncologica</i> , 1994, 33, 693-701.	0.8	50
89	Antagonists of bombesin/gastrin-releasing peptide as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer. <i>Cancer</i> , 1993, 72, 3263-3270.	2.0	16
90	Effect of bombesin, gastrin-releasing peptide (GRP)(14-27) and bombesin/GRP receptor antagonist RC-3095 on growth of nitrosamine-induced pancreatic cancers in hamsters. <i>International Journal of Cancer</i> , 1993, 54, 282-289.	2.3	42

#	ARTICLE	IF	CITATIONS
91	Effect of somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 on growth of PC-3 human prostate-cancer xenografts in nude mice. <i>International Journal of Cancer</i> , 1993, 55, 963-967.	2.3	71
92	Inhibition of growth of experimental prostate cancer in rats by LH-RH analogs linked to cytotoxic radicals. <i>Prostate</i> , 1993, 23, 165-178.	1.2	27
93	Somatostatin analog RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of androgen-independent DU-145 human prostate cancer line in nude mice. <i>Cancer Letters</i> , 1993, 71, 189-196.	3.2	52
94	Growth Inhibition of Estrogen-Dependent and Estrogen-Independent MXT Mammary Cancers in Mice by the Bombesin and Gastrin-Releasing Peptide Antagonist RC-3095. <i>Journal of the National Cancer Institute</i> , 1992, 84, 1915-1922.	3.0	60